Noonan Syndrome (NS)

1. Clinical Overview

Summary

Noonan Syndrome is the most common single-gene cause of congenital heart disease and the prototypical "RASopathy"—a family of developmental disorders caused by germline mutations in the RAS-MAPK (mitogen-activated protein kinase) signaling pathway. [1,2] The syndrome is characterized by distinctive facial dysmorphism, short stature, congenital heart defects (particularly pulmonary valve stenosis and hypertrophic cardiomyopathy), and variable developmental delay. [3]

Unlike Turner syndrome (45,X), which affects only females and predominantly causes left-sided cardiac lesions, Noonan syndrome affects both sexes equally and primarily manifests right-sided cardiac pathology. [4] The condition exhibits autosomal dominant inheritance with remarkable phenotypic variability, even among individuals carrying identical mutations. [5]

Key Facts

• Definition: A multisystem RASopathy disorder characterized by distinctive facial features (hypertelorism, downslanting palpebral fissures, low-set posteriorly rotated ears), congenital heart disease, short stature, webbed neck, chest deformity, cryptorchidism, and variable bleeding diathesis. [3]

• Prevalence: Estimated at 1 in 1,000 to 1 in 2,500 live births, making it one of the most common genetic syndromes affecting children. [6] This prevalence is comparable to Down syndrome in some populations.

• Genetics: Autosomal dominant inheritance with approximately 50% representing de novo mutations. [7] The most frequently mutated gene is PTPN11 (50% of cases), encoding the protein tyrosine phosphatase SHP2. [8] Other causative genes include SOS1 (10-13%), RAF1 (3-17%), RIT1 (5-9%), KRAS (2%), SHOC2 (less than 1%), NRAS, BRAF, and LZTR1. [9,10]

• Pathophysiology: Gain-of-function mutations cause dysregulated activation of the RAS-MAPK signaling cascade, resulting in abnormal cell proliferation, differentiation, and survival during embryonic development and postnatal growth. [11]

• Cardiac Manifestations: Congenital heart disease occurs in 80-90% of patients. [12] Pulmonary valve stenosis (PS) is the most common lesion (50-60%), typically with dysplastic valve morphology. Hypertrophic cardiomyopathy (HCM) occurs in 20-30% and carries significant risk for sudden cardiac death. [13,14]

• Diagnostic Approach: Clinical diagnosis supported by molecular genetic testing (next-generation sequencing RASopathy panel). Echocardiography and comprehensive cardiac assessment are mandatory at diagnosis. [15]

Clinical Pearls

The "Male Turner" Misconception: Historically termed "Male Turner Syndrome" due to phenotypic overlap (webbed neck, short stature, lymphedema). However, critical distinctions exist: Turner syndrome (45,X) affects only females with left-sided cardiac defects (coarctation of aorta, bicuspid aortic valve), whereas Noonan syndrome affects both sexes with right-sided lesions (pulmonary stenosis). The chromosomal karyotype in Noonan syndrome is normal (46,XX or 46,XY). [4]

The Coagulation Trap: Approximately 40-65% of individuals with Noonan syndrome have bleeding abnormalities, including factor deficiencies (Factor XI, XII, VIII, von Willebrand factor) and platelet dysfunction. [16] Crucially, routine coagulation screening (PT/aPTT) may be normal despite significant surgical bleeding risk. Always obtain comprehensive hemostasis evaluation (including factor assays and platelet function testing) prior to any surgical procedure, including seemingly minor interventions like tonsillectomy or dental extractions.

Genotype-Phenotype Correlations: The causative gene significantly influences phenotype. [17] PTPN11 mutations typically associate with pulmonary stenosis, relatively preserved cognition, and classic facial features. RAF1 mutations confer exceptionally high risk (75-95%) of severe hypertrophic cardiomyopathy requiring aggressive surveillance. [18] RIT1 mutations associate with increased lymphatic complications (hydrops fetalis, chylothorax). [19] KRAS mutations correlate with more severe intellectual disability and increased risk of Costello syndrome overlap features.

Anesthetic Risk Stratification: Noonan syndrome patients are high-risk anesthetic candidates. [20] Potential airway difficulties arise from micrognathia, short webbed neck, and limited neck extension. Cardiac risks include dynamic left ventricular outflow tract obstruction in HCM (worsened by hypovolemia, tachycardia, or positive inotropes) and right heart failure in severe PS. Bleeding diathesis may manifest intraoperatively despite normal preoperative coagulation parameters. Mandatory preoperative cardiology clearance, detailed hemostasis plan, and availability of advanced airway equipment are essential.

Why This Matters Clinically

Noonan syndrome frequently presents with subtle manifestations leading to delayed diagnosis. [21] A child evaluated at age 8 years for "idiopathic short stature" or "clumsiness" may have missed critical windows for growth hormone therapy and cardiac surveillance. More importantly, undiagnosed hypertrophic cardiomyopathy carries risk of sudden cardiac death during physical exertion—a potentially preventable tragedy through timely diagnosis and activity modification. [13]

The recognition of Noonan syndrome as a RASopathy has transformative therapeutic implications. Ongoing clinical trials of MEK inhibitors (trametinib) demonstrate promise in reversing severe hypertrophic cardiomyopathy, potentially offering disease-modifying treatment beyond symptomatic management. [22]

---

2. Epidemiology

Incidence & Prevalence

General Population: Birth prevalence estimates range from 1:1,000 to 1:2,500 live births based on population studies. [6] A recent multicenter European study reported prevalence of 1:1,000, establishing Noonan syndrome among the most common monogenic disorders affecting children. [23] This prevalence approaches that of Down syndrome (1:700) and exceeds conditions like cystic fibrosis (1:3,500 in Caucasians).

Sex Distribution: Equal male-to-female ratio (1:1), consistent with autosomal dominant inheritance. [3] Historical overrepresentation of males in clinical series likely reflects ascertainment bias due to cryptorchidism prompting genetic evaluation.

Geographic and Ethnic Variation: Noonan syndrome occurs across all ethnic groups and geographic regions without significant population-specific prevalence differences. However, founder mutations in specific populations have been reported, including recurrent LZTR1 mutations in consanguineous families. [10]

Genetic Epidemiology

Inheritance Pattern: Autosomal dominant with near-complete penetrance but highly variable expressivity. [7] Approximately 50% of cases represent de novo mutations, while 50% are familial (inherited from an affected parent). [5]

Parental Age Effect: Advanced paternal age associates with increased risk of de novo mutations, particularly in PTPN11. [24] The paternal age effect reflects increased DNA replication errors in spermatogenesis.

Molecular Epidemiology:

• PTPN11: 50% of clinically diagnosed cases [8]
• SOS1: 10-13% [9]
• RAF1: 3-17% [18]
• RIT1: 5-9% [19]
• KRAS: ~2% [9]
• NRAS, SHOC2, BRAF, LZTR1: Collectively less than 5% [10]
• Genetically unsolved: 10-20% of clinically diagnosed cases remain without identified pathogenic variant despite comprehensive sequencing, suggesting additional undiscovered genes [9]

Recurrence Risk Counseling:

• Affected individual: 50% transmission risk to each offspring
• Unaffected parents with one affected child (presumed de novo): Low recurrence risk (less than 1%), though germline mosaicism cannot be completely excluded
• Prenatal diagnosis available via chorionic villus sampling or amniocentesis for known familial mutations

Risk Factors for Severe Phenotype

While Noonan syndrome itself results from genetic mutation rather than environmental risk factors, certain genotypes predict more severe clinical manifestations:

High-Risk Genotypes:

• RAF1 mutations: 75-95% risk of severe hypertrophic cardiomyopathy, often progressive and refractory to medical therapy [18]
• RIT1 mutations: Increased incidence of fetal hydrops, neonatal chylothorax, and severe lymphatic dysfunction [19]
• KRAS mutations: Higher rates of moderate-to-severe intellectual disability and developmental delay [9]

---

3. Pathophysiology

The RAS-MAPK Signaling Pathway

The RAS-MAPK cascade represents a fundamental intracellular signaling pathway regulating cell proliferation, differentiation, migration, and survival. [11] This evolutionarily conserved pathway transmits signals from cell surface receptors (particularly receptor tyrosine kinases) to nuclear transcription factors, ultimately controlling gene expression.

Normal Pathway Architecture:

1. Extracellular ligand (growth factor) binds receptor tyrosine kinase (RTK)
2. Activated RTK recruits SOS1 (guanine nucleotide exchange factor)
3. SOS1 activates RAS by promoting GTP loading
4. RAS-GTP activates RAF (MAPK kinase kinase)
5. RAF phosphorylates MEK (MAPK kinase)
6. MEK phosphorylates ERK (MAPK)
7. Phosphorylated ERK translocates to nucleus, activating transcription factors
8. Negative regulation by PTPN11 (SHP2 phosphatase) and other feedback mechanisms

Pathogenic Mechanism in Noonan Syndrome: The mutations causing Noonan syndrome are predominantly gain-of-function, resulting in excessive or prolonged RAS-MAPK pathway activation. [11] This pathologic hyperactivation during critical developmental windows produces the multisystem manifestations of the syndrome.

Molecular Mechanisms by Gene

PTPN11 (SHP2 Phosphatase): The most commonly mutated gene encodes SHP2, a protein tyrosine phosphatase with complex regulatory functions. [8] Pathogenic PTPN11 mutations cluster in the N-SH2 and catalytic (PTP) domains, disrupting auto-inhibition and causing constitutive phosphatase activity. Paradoxically, this gain-of-function phosphatase activity results in RAS-MAPK hyperactivation through enhanced GRB2-SOS complex formation. [25]

SOS1 (Guanine Nucleotide Exchange Factor): SOS1 mutations enhance GDP-to-GTP exchange on RAS, prolonging RAS activation. [26] These gain-of-function mutations produce constitutive pathway activation independent of upstream receptor signals.

RAF1 (MAPK Kinase Kinase): RAF1 mutations disrupt regulatory phosphorylation sites or alter protein interactions, resulting in excessive MEK activation. [18] The severe cardiac phenotype (particularly HCM) associated with RAF1 mutations likely reflects tissue-specific sensitivity of cardiac myocytes to dysregulated MAPK signaling during development and postnatal growth.

RIT1 (RAS-like GTPase): RIT1 is a RAS-related small GTPase. Pathogenic mutations impair GTPase activity, causing accumulation of RIT1-GTP and sustained pathway activation. [19] RIT1 mutations show particularly strong association with lymphatic abnormalities, suggesting tissue-specific roles in lymphangiogenesis.

Organ System Pathophysiology

Cardiac Development: Dysregulated RAS-MAPK signaling during cardiac morphogenesis disrupts:

• Endocardial cushion development → dysplastic, thickened valve leaflets (pulmonary stenosis) [12]
• Cardiomyocyte proliferation and organization → asymmetric septal hypertrophy (HCM) [13]
• Coronary artery development → abnormal coronary origins/courses (10-20% of cases)

The bimodal cardiac phenotype (stenotic vs. hypertrophic) likely reflects temporal and dose-dependent effects of pathway hyperactivation during different developmental stages.

Skeletal Growth: Short stature in Noonan syndrome results from multiple mechanisms: [27]

• Relative growth hormone (GH) resistance at the tissue level despite normal or elevated GH secretion
• Reduced IGF-1 generation in response to GH
• Intrinsic chondrocyte dysfunction affecting growth plate biology
• Spinal abnormalities (kyphoscoliosis, vertebral anomalies)

Unlike GH deficiency, where exogenous GH simply replaces missing hormone, Noonan syndrome requires supraphysiologic GH doses to overcome partial resistance. [27]

Hemostasis: The mechanisms underlying bleeding diathesis remain incompletely understood but include: [16]

• Reduced synthesis of specific coagulation factors (XI, XII, VIII, von Willebrand factor)
• Platelet function defects (storage pool deficiency, impaired aggregation)
• Possible direct effects of dysregulated MAPK signaling on megakaryocyte development

Lymphatic System: RAS-MAPK pathway hyperactivation disrupts lymphangiogenesis and lymphatic vessel integrity, resulting in: [28]

• Fetal: Increased nuchal translucency, cystic hygroma, hydrops fetalis
• Neonatal/Infant: Peripheral lymphedema (puffy hands/feet), chylothorax
• Later childhood: Intestinal lymphangiectasia, protein-losing enteropathy

Neurodevelopment: Dysregulated RAS-MAPK signaling affects neuronal migration, dendritic arborization, and synaptic plasticity. [29] The molecular mechanisms underlying cognitive impairment in RASopathies are being actively investigated, with preclinical studies suggesting partial reversibility with MEK inhibitors.

The RASopathy Spectrum: Genotype-Phenotype Continuum

Noonan syndrome exists on a phenotypic continuum with related RASopathies, reflecting allelic and non-allelic heterogeneity: [2]

Clinical Pearl: When a patient presents with features suggestive of Noonan syndrome but exhibits severe intellectual disability and prominent ectodermal features (ichthyosis, severe eczema, sparse hair), consider CFC syndrome. Conversely, thousands of lentigines developing in later childhood in a patient with HCM suggest NSML rather than classic Noonan syndrome. [30]

Genotype-Phenotype Correlations (Detailed)

These genotype-phenotype correlations inform prognosis, guide surveillance strategies, and facilitate genetic counseling. [17]

---

4. Clinical Presentation

Neonatal Presentation

Facial Dysmorphism (present from birth but may be subtle):

• Hypertelorism: Widely spaced eyes (increased interpupillary distance)
• Downslanting palpebral fissures: Outer eye corners positioned lower than inner corners
• Ptosis: Droopy upper eyelids (unilateral or bilateral)
• Low-set, posteriorly rotated ears: Ears positioned below horizontal line through outer canthus, rotated backward
• Webbed neck (pterygium colli): Excess nuchal skin folds extending from mastoid to acromion
• High arched palate: Often accompanied by dental malocclusion in older children

Cardiac Findings:

• Heart murmur detected on newborn examination (50-60%) [12]
• Ejection systolic murmur at upper left sternal border (pulmonary stenosis)
• Clinical signs of heart failure rare unless critical PS or severe HCM present

Lymphatic Manifestations:

• Dorsal edema of hands and feet (puffy extremities) [28]
• Nuchal edema/cystic hygroma (may be detected prenatally on ultrasound)
• Chylothorax (particularly in RIT1-associated cases)

Feeding Difficulties:

• Poor suck-swallow coordination [31]
• Gastroesophageal reflux
• Failure to thrive affecting 30-40% of infants
• May require nasogastric or gastrostomy feeding support

Genitourinary:

• Cryptorchidism: Undescended testes in 60-80% of males [32]
• Renal anomalies (10-15%): duplicated collecting system, hydronephrosis, renal ectopia

Evolution of Facial Phenotype

The facial gestalt of Noonan syndrome evolves significantly with age, potentially causing diagnostic challenges: [3]

Infancy (0-2 years):

• Most distinctive dysmorphic period
• Prominent forehead, depressed nasal bridge
• Puffy eyelids, hypertelorism very apparent
• Webbed neck most evident

Early Childhood (2-10 years):

• Face begins to elongate, developing triangular configuration
• Features may appear to "normalize" somewhat, making diagnosis less obvious
• Curly or woolly hair becomes more apparent
• Low-set ears remain prominent finding

Adolescence and Adulthood:

• Features become coarser
• High anterior hairline, receding temporal hairline
• Facial phenotype may be quite subtle in adults, particularly in mildly affected individuals
• Webbing of neck less apparent due to increased muscle mass

Clinical Implication: The most phenotypically distinctive period is infancy. Failure to recognize Noonan syndrome at this stage may lead to delayed diagnosis until manifestations like short stature, learning difficulties, or cardiac complications prompt re-evaluation in later childhood.

Thoracic and Skeletal Features

Chest Deformity (80-90% of cases): [33]

• Superior pectus carinatum: Protuberant upper sternum ("pigeon chest")
• Inferior pectus excavatum: Depression of lower sternum and xiphoid ("funnel chest")
• This combination creates characteristic "shield chest" appearance with increased internipple distance
• Usually asymptomatic but may cause cosmetic concerns in adolescence

Spinal Abnormalities:

• Vertebral anomalies (10-20%): wedged vertebrae, spina bifida occulta
• Scoliosis (10-15%), may progress during adolescent growth spurt
• Kyphosis less common but can be severe when present

Joint Features:

• Joint hypermobility and hyperextensibility (particularly fingers, elbows)
• May contribute to gross motor clumsiness and delayed motor milestones

Growth Pattern

Birth Parameters: Birth weight and length typically normal (mean birth weight 50th centile), though approximately 20% are small for gestational age. [27]

Postnatal Growth Failure: Progressive deceleration becomes apparent in infancy:

• By age 2 years, mean height approximately -2 SD (2nd centile)
• Without intervention, adult height approximately 162 cm (males) and 153 cm (females), representing -2.3 to -2.5 SD [27]
• Growth velocity often remains at low-normal rates (4-5 cm/year during childhood) but cumulative deficit increases
• Puberty typically delayed by 1.5-2 years, reducing pubertal height gain

Specialized Growth Charts: Noonan syndrome-specific growth charts have been developed and should be used for monitoring rather than standard population charts. [34] These facilitate distinction between expected Noonan-associated short stature versus superimposed pathology (hypothyroidism, growth hormone deficiency).

Cardiac Manifestations (Detailed)

Prevalence: Congenital heart disease present in 80-90%, making it the most consistent major malformation. [12]

Pulmonary Valve Stenosis (50-60%):

• Most common cardiac lesion [12]
• Typically dysplastic valve morphology: thickened, fleshy, immobile leaflets with poorly developed commissures
• Distinct from typical dome-shaped stenosis with thin, fused leaflets seen in non-syndromic PS
• Dysplastic morphology predicts poor response to balloon valvuloplasty (higher failure/restenosis rates)
• Peak gradient determines severity:
  • "Mild: less than 40 mmHg"
  • "Moderate: 40-60 mmHg"
  • "Severe: > 60 mmHg"
• May be progressive, requiring serial echocardiographic surveillance

Hypertrophic Cardiomyopathy (20-30%):

• Second most common cardiac manifestation [13]
• Typically asymmetric septal hypertrophy, similar to familial HCM
• May present at birth or develop during childhood/adolescence (requires serial screening)
• Strong genotype association: RAF1 (75-95%), RIT1 (70%), PTPN11 (6%)
• Clinical spectrum ranges from asymptomatic to severe left ventricular outflow tract obstruction
• Risk factors for adverse outcomes: [14]
  • Severe septal hypertrophy (> 3 cm)
  • Left ventricular outflow tract gradient > 50 mmHg
  • Sustained ventricular tachycardia
  • Syncope or family history of sudden death
• Sudden cardiac death risk: Estimated 2-4% in Noonan-associated HCM, necessitating activity restrictions and ICD consideration in high-risk patients

Atrial Septal Defect (10%):

• Secundum type most common
• Often small and hemodynamically insignificant
• May close spontaneously in early childhood

Other Cardiac Lesions (10-15%):

• Ventricular septal defect (typically perimembranous)
• Atrioventricular septal defect (AVSD)
• Mitral valve dysplasia/insufficiency
• Aortic stenosis (rare, less than 5%)
• Peripheral pulmonary stenosis (branch pulmonary artery stenosis)
• Complex congenital heart disease (rare)
• Coronary artery anomalies (10-20%): aberrant origins, myocardial bridging

Arrhythmias:

• Wolff-Parkinson-White syndrome (10% of HCM cases)
• Supraventricular tachycardia
• Ventricular arrhythmias (particularly in HCM)

Hematologic Manifestations

Bleeding Diathesis (40-65%): [16]

Multiple mechanisms contribute to hemorrhagic tendency:

Coagulation Factor Deficiencies:

• Factor XI deficiency (most common, 50-60% of bleeding cases)
• Factor XII deficiency (frequently asymptomatic)
• Factor VIII deficiency or reduced activity
• Von Willebrand disease (reduced vWF antigen or activity)
• Combined factor deficiencies possible

Platelet Dysfunction:

• Platelet aggregation defects
• Storage pool deficiency
• Reduced platelet glycoprotein expression
• Thrombocytopenia (less common)

Clinical Manifestations:

• Easy bruising (most common symptom)
• Prolonged bleeding from minor cuts
• Epistaxis (nosebleeds)
• Menorrhagia in adolescent females
• Excessive surgical bleeding (especially tonsillectomy, dental extractions, cardiac surgery)

Diagnostic Challenge: Routine coagulation screening (PT, aPTT) may be normal in up to 50% of patients with clinically significant bleeding tendency. Comprehensive evaluation requires:

• PT, aPTT, fibrinogen
• Individual factor assays (VIII, IX, XI, XII)
• Von Willebrand panel (vWF antigen, vWF activity, vWF multimers)
• Platelet function testing (PFA-100, aggregometry)
• Bleeding time (now largely replaced by PFA-100)

Myeloproliferative Disorders:

• Juvenile myelomonocytic leukemia (JMML): rare but important association [35]
• Presents in infancy with hepatosplenomegaly, monocytosis, thrombocytopenia
• Risk particularly elevated in PTPN11 and KRAS mutations
• Transient myeloproliferative disorder may occur in neonatal period and spontaneously resolve

Neurodevelopmental Profile

Cognitive Function: [29]

• Mean IQ approximately 85-90 (low-normal range), representing 1 SD below population mean
• Distribution shows leftward shift: 15-30% have IQ less than 70 (intellectual disability threshold)
• Genotype strongly influences cognitive outcome:
  • "SOS1: Usually normal IQ (95-105)"
  • "PTPN11: Borderline to low-normal (85-100)"
  • "RAF1: Mild impairment (80-90)"
  • "KRAS: Moderate to severe impairment (60-75)"

Specific Cognitive Deficits (disproportionate to general IQ):

• Visual-spatial processing: Most consistent neuropsychological deficit
• Executive function difficulties (planning, organization, working memory)
• Processing speed deficits
• Relative preservation of verbal skills

Motor Development:

• Gross motor delay common (70-80%): delayed walking (mean 18 months), clumsiness
• Hypotonia (low muscle tone) in infancy
• Joint hypermobility contributing to motor coordination difficulties
• Fine motor skills usually less affected

Speech and Language:

• Articulation difficulties (30-40%) due to palatal abnormalities and oral motor dysfunction
• Language development mildly delayed in 30-50%
• Social communication generally preserved

Behavioral and Psychiatric Features:

• Attention-deficit/hyperactivity disorder (ADHD): 25-40%
• Anxiety disorders: 20-30%, particularly social anxiety
• Autism spectrum disorder (ASD): 10-15%, higher than general population [36]
• Generally described as sociable, pleasant temperament

Educational Implications:

• 30-50% require special education support or individualized education plans
• Specific learning disabilities common, particularly affecting mathematics and visual-spatial tasks
• Early intervention (speech therapy, occupational therapy, physical therapy) improves outcomes

Lymphatic System Manifestations

Prenatal/Fetal: [28]

• Increased nuchal translucency on first-trimester ultrasound (11-14 weeks)
• Cystic hygroma (lymphatic malformation of neck)
• Hydrops fetalis (generalized edema): particularly associated with RIT1 mutations [19]
• Polyhydramnios (excessive amniotic fluid) secondary to fetal swallowing dysfunction

Neonatal:

• Dorsal lymphedema of hands and feet (puffy extremities)
• Chylothorax: accumulation of chyle (lymphatic fluid) in pleural space
  • May occur spontaneously or following thoracic surgery
  • Presents with respiratory distress, pleural effusion on chest X-ray
  • Diagnosed by pleural fluid analysis (milky appearance, elevated triglycerides > 110 mg/dL, lymphocytosis)

Childhood and Adolescence:

• Peripheral lymphedema (typically lower extremities)
• Intestinal lymphangiectasia: dilation of intestinal lymphatic vessels
  • Protein-losing enteropathy with hypoalbuminemia
  • Chronic diarrhea, abdominal pain
  • Malabsorption and growth failure
• Pulmonary lymphangiectasia (rare)

Genitourinary Features

Males (60-80% affected): [32]

• Cryptorchidism (undescended testes): bilateral (30-40%) or unilateral (40-50%)
• Typically inguinal position (rather than intra-abdominal)
• Spontaneous descent less common than isolated cryptorchidism
• Orchiopexy recommended by 12-18 months to preserve fertility potential and reduce malignancy risk
• Reduced testicular volume even after orchiopexy
• Fertility: Variable; studies report 40-60% successful paternity with increased rates of oligospermia
• Sertoli cell dysfunction: Recent evidence suggests primary testicular insufficiency independent of cryptorchidism [37]

Females:

• Delayed puberty (50-60%): menarche delayed by 1.5-2 years on average
• Fertility generally preserved, though limited data available
• Menorrhagia may occur due to bleeding diathesis
• Successful pregnancy common, though increased obstetric risks (preterm delivery, postpartum hemorrhage)

Renal Anomalies (10-15%):

• Duplex collecting system
• Hydronephrosis (may be secondary to posterior urethral valves or vesicoureteral reflux)
• Renal ectopia or malrotation
• Rarely, significant structural anomalies (horseshoe kidney, multicystic dysplastic kidney)

Ophthalmologic Features (50-95%)

• Refractive errors: Myopia, hyperopia, astigmatism (95%)
• Strabismus (esotropia or exotropia): 40-50%
• Ptosis (blepharoptosis): 30-50%, may be unilateral or bilateral
• Amblyopia ("lazy eye"): 20-30%, often secondary to strabismus or uncorrected refractive error
• Nystagmus: 15-25%
• Fundoscopic findings: Optic nerve hypoplasia, tortuous retinal vessels (less common)

Routine ophthalmologic screening recommended at diagnosis and periodically throughout childhood.

Auditory Features (10-40%)

• Sensorineural hearing loss: 10-40%, typically mild to moderate [38]
• Conductive hearing loss: Secondary to chronic otitis media with effusion (common due to palatal dysfunction and Eustachian tube abnormalities)
• Progressive hearing loss may occur
• Routine audiologic screening recommended at diagnosis and every 2-3 years

Dermatologic Features

• Keratosis pilaris: Rough, bumpy skin texture (particularly upper arms, thighs)—especially prominent in SOS1 mutations
• Curly or woolly hair: Coarse, tightly curled hair
• Sparse eyebrows and eyelashes
• Multiple pigmented nevi (moles): Particularly RAF1 mutations
• Ulerythema ophryogenes: Follicular atrophy affecting eyebrows (rare)
• Lymphedema-associated skin changes: Thickened, indurated skin overlying areas of chronic lymphedema

Other System Involvement

Endocrine:

• Relative growth hormone insensitivity (mechanism of short stature) [27]
• Hypothyroidism (5-10%): May be congenital or acquired
• Delayed puberty (50-60%)

Dental:

• Malocclusion (misaligned teeth)
• High arched palate
• Delayed tooth eruption
• Enamel hypoplasia
• Increased caries risk

Gastrointestinal:

• Gastroesophageal reflux disease
• Feeding difficulties and failure to thrive in infancy [31]
• Protein-losing enteropathy (secondary to intestinal lymphangiectasia)
• Hepatomegaly (particularly if myeloproliferative disorder present)

---

5. Differential Diagnosis

The distinctive constellation of findings in Noonan syndrome—dysmorphic facies, cardiac defects, short stature—overlaps with several other genetic conditions. Distinguishing features guide appropriate genetic testing and management.

Diagnostic Approach When Differential is Broad:

1. Chromosomal microarray: Identifies Turner syndrome (45,X), Williams syndrome (7q11.23 deletion), and other chromosomal abnormalities
2. RASopathy gene panel: Sequences PTPN11, SOS1, RAF1, RIT1, KRAS, NRAS, BRAF, HRAS, MEK1, MEK2, SHOC2, LZTR1, CBL
3. Targeted testing based on clinical features:
   • Prominent lentigines → PTPN11 (NSML-specific mutations), RAF1, BRAF
   • Severe ectodermal features → CFC panel (BRAF, MEK1, MEK2)
   • Papillomas, severe ID → Costello (HRAS)
4. Exome/genome sequencing if panel negative but clinical suspicion high

Clinical Pearl: In a neonate with hydrops fetalis and features suggestive of Noonan syndrome, strongly consider RIT1 testing first, as this genotype shows high association with severe lymphatic dysfunction. [19]

---

6. Investigations

Initial Diagnostic Workup

When Noonan syndrome is suspected based on clinical phenotype, systematic evaluation should establish diagnosis, define extent of organ system involvement, and guide surveillance:

1. Molecular Genetic Testing [15]

• First-line: Next-generation sequencing RASopathy panel including:
  • "Core genes: PTPN11, SOS1, RAF1, RIT1, KRAS, NRAS, BRAF, SHOC2, LZTR1, CBL"
  • "Extended genes (depending on panel): MAP2K1, MAP2K2, RRAS, RASA2, MRAS, A2ML1"
• Diagnostic yield: Identifies pathogenic variant in 70-80% of clinically diagnosed cases
• Interpretation: Requires expert genetic analysis; many variants of uncertain significance (VUS) identified
• Turnaround time: Typically 4-8 weeks
• Trio analysis: Testing unaffected parents helps distinguish de novo from inherited variants and clarifies VUS pathogenicity

If panel negative but clinical diagnosis highly likely: Consider exome or genome sequencing to identify potential novel genes

2. Cardiac Evaluation [12,15]

• Echocardiography (transthoracic):
  • Assess valve morphology and function (particular attention to pulmonary valve)
  • Measure transvalvar gradients (pulmonary, aortic)
  • Assess ventricular wall thickness (septal, posterior wall, free wall)
  • Evaluate for septal defects (ASD, VSD)
  • Assess mitral and tricuspid valves
  • Evaluate left ventricular outflow tract (LVOT) for dynamic obstruction
• Electrocardiogram (ECG):
  • May show left ventricular hypertrophy (HCM)
  • Left axis deviation common
  • Evaluate for pre-excitation (Wolff-Parkinson-White pattern)
  • Assess PR interval (prolonged in NSML)
• Chest X-ray: Cardiac silhouette, pulmonary vascularity
• Consider:
  • 24-hour Holter monitor if arrhythmia suspected or HCM present
  • Exercise stress test in HCM to assess exercise-induced arrhythmias and abnormal blood pressure response
  • Cardiac MRI for detailed myocardial assessment in HCM, evaluation of coronary artery anatomy

3. Hematologic Assessment [16]

• Complete blood count (CBC) with differential:
  • Evaluate for thrombocytopenia, anemia
  • Assess for myeloproliferative disorder (monocytosis, abnormal white cell differential) if infant with splenomegaly
• Coagulation screening:
  • PT (prothrombin time)
  • aPTT (activated partial thromboplastin time)
  • Fibrinogen
• Extended coagulation studies (especially if surgery planned or bleeding history):
  • Factor VIII, IX, XI, XII assays
  • "Von Willebrand panel: vWF antigen, vWF activity (ristocetin cofactor), vWF multimers"
  • Platelet function testing (PFA-100 or platelet aggregometry)

4. Growth and Endocrine Assessment

• Auxology:
  • Height, weight, head circumference plotted on Noonan-specific growth charts [34]
  • Mid-parental height calculation
  • Growth velocity assessment (serial measurements)
• Bone age (left hand/wrist X-ray): Often delayed 1-2 years
• IGF-1 and IGFBP-3: Assess GH-IGF axis (typically low-normal despite normal GH secretion)
• Thyroid function (TSH, free T4): Screen for hypothyroidism
• Consider growth hormone stimulation testing if growth failure severe, though GH deficiency rare

5. Renal and Genitourinary

• Renal ultrasound: Assess for structural anomalies, hydronephrosis
• Males: Physical examination documenting testicular position (for orchiopexy planning if cryptorchid)

6. Developmental Assessment

• Formal developmental evaluation (Bayley Scales in infants/toddlers)
• Neuropsychological testing in school-age children (IQ, visual-spatial processing, executive function)
• Speech and language evaluation if language delay apparent
• Occupational therapy evaluation for fine motor skills
• Physical therapy evaluation for gross motor delay/hypotonia

7. Ophthalmologic and Audiologic

• Comprehensive eye examination: Refractive error, strabismus, ptosis
• Audiometry: Hearing assessment (auditory brainstem response in infants; behavioral audiometry in older children)

8. Imaging for Associated Anomalies

• Spine X-rays if scoliosis/kyphosis suspected
• Consider skeletal survey if multiple skeletal abnormalities suspected

Prenatal Diagnosis

Indications:

• Known familial mutation (affected parent or previously affected child with identified pathogenic variant)
• Abnormal prenatal ultrasound findings suggestive of Noonan syndrome

Prenatal Ultrasound Findings suggestive of Noonan/RASopathy: [39]

• Increased nuchal translucency (11-14 weeks): > 3.5 mm
• Cystic hygroma (neck lymphatic malformation)
• Hydrops fetalis (generalized edema): skin edema, ascites, pleural/pericardial effusions
• Polyhydramnios (excessive amniotic fluid)
• Cardiac defects: Particularly pulmonary stenosis, hypertrophic cardiomyopathy
• Renal anomalies

Prenatal Genetic Testing Options:

• Chorionic villus sampling (CVS): 11-14 weeks gestation
• Amniocentesis: 15-20 weeks gestation
• Cell-free fetal DNA testing (non-invasive prenatal testing): Research stage for single-gene disorders; not yet standard for Noonan syndrome
• DNA extracted from fetal cells tested via targeted mutation analysis (if familial mutation known) or RASopathy panel

Genetic Counseling: Essential component of prenatal diagnosis process, discussing implications, accuracy/limitations of testing, reproductive options

Surveillance Investigations

Once diagnosis established, longitudinal monitoring protocols detect complications early:

Cardiac Surveillance: [15]

• Baseline: Comprehensive echocardiogram and ECG at diagnosis
• Ongoing:
  • "If normal baseline cardiac evaluation: Repeat echo every 3-5 years (HCM may develop de novo)"
  • "If pulmonary stenosis: Echo every 1-2 years, more frequently if moderate-severe"
  • "If HCM: Echo every 6-12 months, ECG annually, consider Holter monitoring"
  • Cardiology follow-up as clinically indicated

Growth Monitoring:

• Height, weight every 3-6 months during childhood
• Plot on Noonan-specific growth charts [34]
• Bone age every 1-2 years if considering growth hormone therapy

Developmental/Educational:

• Developmental screening at routine pediatric visits
• Comprehensive neuropsychological evaluation at school entry (age 5-6) and when academic difficulties emerge
• Monitor for ADHD, anxiety symptoms

Ophthalmology:

• Baseline comprehensive examination
• Follow-up every 1-2 years or as recommended by ophthalmologist

Audiology:

• Baseline hearing assessment
• Repeat every 2-3 years, more frequently if hearing loss identified

Hematology:

• Coagulation screening before any surgical procedure
• In infancy with PTPN11 or KRAS mutations: Monitor for signs of JMML (hepatosplenomegaly, CBC abnormalities)

Other:

• Annual thyroid function testing (TSH)
• Spine examination for scoliosis during growth spurts
• Renal ultrasound at diagnosis; repeat only if abnormal or symptoms develop

---

7. Management

Management of Noonan syndrome requires multidisciplinary coordination addressing cardiac, endocrine, hematologic, developmental, and psychosocial needs. No disease-modifying therapy currently exists for the underlying RASopathy, so treatment remains largely supportive and complication-directed. However, emerging MEK inhibitor trials may change this paradigm. [22]

Multidisciplinary Team Composition

Optimal care involves: [15]

• Clinical geneticist: Coordinates diagnosis, genetic counseling, family screening
• Pediatric cardiologist: Manages cardiac manifestations, surveillance for HCM
• Pediatric endocrinologist: Growth hormone therapy, pubertal development
• Hematologist: Bleeding diathesis management, perioperative planning
• Developmental pediatrician/Neurologist: Developmental delays, ADHD, behavioral issues
• Speech therapist, Occupational therapist, Physical therapist: Developmental interventions
• Ophthalmologist, Audiologist: Sensory impairments
• Urologist (for males with cryptorchidism)
• Educational psychologist: Learning support, individualized education plans
• Genetic counselor: Family planning, recurrence risk counseling

Cardiac Management

Pulmonary Valve Stenosis: [12]

Severity Stratification:

• Mild (peak gradient less than 40 mmHg): Observation, no intervention required
• Moderate (peak gradient 40-60 mmHg): Consider intervention if symptomatic (exercise intolerance, right ventricular dysfunction)
• Severe (peak gradient > 60 mmHg): Intervention indicated

Intervention Options:

• Balloon valvuloplasty (transcatheter):

  • First-line intervention for non-dysplastic pulmonary stenosis
  • Less successful in Noonan syndrome due to dysplastic valve morphology (thickened, immobile leaflets)
  • Success rate ~60% (vs. 85-90% in non-syndromic PS)
  • Higher restenosis rates
  • Still attempted as initial strategy to avoid surgery

• Surgical valvotomy:

  • Often required due to dysplastic valve morphology
  • Open surgical approach with direct visualization
  • May require valve replacement if severe dysplasia (typically pulmonary homograft or bioprosthetic valve)

Follow-up:

• Cardiology follow-up every 6-12 months
• Serial echocardiography to monitor gradient progression
• Endocarditis prophylaxis not routinely recommended for isolated PS (per current AHA guidelines)

Hypertrophic Cardiomyopathy (HCM): [13,14]

Risk Stratification:

• Degree of hypertrophy (septal thickness)
• Presence/severity of LVOT obstruction (gradient > 50 mmHg)
• Arrhythmias (non-sustained or sustained ventricular tachycardia)
• Syncope or presyncope
• Family history of sudden cardiac death
• Abnormal blood pressure response to exercise

Medical Management:

• Beta-blockers (first-line):

  • Propranolol 1-4 mg/kg/day divided BID-TID, or
  • Atenolol 1-2 mg/kg/day once daily
  • "Mechanism: Negative chronotropic/inotropic effects reduce LVOT obstruction, improve diastolic filling"
  • Titrate to resting heart rate 60-70 bpm

• Calcium channel blockers (second-line):

  • Verapamil (avoid in infants less than 1 year due to risk of cardiac arrest)
  • Used if beta-blockers contraindicated or ineffective

• Disopyramide (adjunct therapy):

  • Class Ia antiarrhythmic with negative inotropic effect
  • May reduce LVOT gradient in refractory cases
  • Requires careful monitoring (anticholinergic side effects, proarrhythmic potential)

Interventional/Surgical Management:

• Septal myectomy (Morrow procedure):

  • Surgical resection of hypertrophied basal septum
  • Indicated for severe symptoms refractory to medical therapy with LVOT gradient > 50 mmHg
  • Excellent outcomes in experienced centers

• Alcohol septal ablation:

  • Percutaneous injection of alcohol into septal perforator artery causing controlled myocardial infarction
  • Less commonly used in pediatric populations
  • Concerns about late arrhythmogenic scar

• Implantable cardioverter-defibrillator (ICD):

  • Primary prevention in high-risk patients (syncope, family history sudden death, massive LVH, NSVT)
  • Shared decision-making balancing sudden death risk vs. device complications

Activity Restrictions:

• Competitive sports participation restricted in moderate-severe HCM
• Individualized based on HCM severity, genotype, arrhythmia risk
• Follow American Heart Association/European Society of Cardiology eligibility guidelines

Novel Therapies (Emerging):

• MEK inhibitors (trametinib): [22]
  • Directly target dysregulated MAPK pathway
  • Clinical trials demonstrating regression of HCM and improvement in LVOT gradients in RASopathy-associated HCM
  • FDA granted Breakthrough Therapy designation for trametinib in RASopathy-associated HCM (2024)
  • Potential paradigm shift from symptomatic management to disease-modifying therapy
  • "Adverse effects: Rash, diarrhea, edema, potential effects on growth/development (under investigation)"

Other Cardiac Lesions:

• ASD/VSD: Surgical or transcatheter closure if hemodynamically significant (Qp:Qs > 1.5:1, right ventricular dilation)
• Arrhythmias: Standard antiarrhythmic protocols; catheter ablation for refractory SVT or accessory pathways

Growth and Endocrine Management

Growth Hormone Therapy: [27]

Rationale:

• Noonan syndrome involves partial GH resistance/insensitivity rather than GH deficiency
• GH levels normal or elevated, but IGF-1 response blunted
• Supraphysiologic GH doses overcome partial resistance

Indications:

• Height -2.25 SD or less (approximately less than 2nd centile on standard charts)
• Growth velocity less than 25th centile for age
• Age ≥4 years (some protocols start earlier)

FDA Approval:

• Recombinant human growth hormone (rhGH) FDA-approved for Noonan syndrome (2007) [27]

Dosing:

• Higher than GH deficiency: 0.033-0.066 mg/kg/day subcutaneously (daily injection)
• Typically ~0.05 mg/kg/day used initially

Expected Outcomes:

• Improvement in height velocity from ~4 cm/year to ~7-8 cm/year during first year
• Near-adult height gain of 1.3-1.8 SD (~8-13 cm) with multi-year treatment [34]
• Benefit greatest when started early (age 4-6 years) and continued until growth plates fuse

Monitoring During GH Therapy:

• Growth velocity and height every 3-6 months
• IGF-1 and IGFBP-3 levels: Maintain IGF-1 in upper-normal range
• Cardiac surveillance: Echocardiogram every 6-12 months
  • "Theoretical concern: GH may worsen HCM"
  • "Evidence: Studies show no significant increase in left ventricular mass with GH treatment [27]"
  • "Contraindication: Severe, progressive HCM (relative contraindication requiring individualized decision)"
• Thyroid function (TSH, free T4) annually: GH can unmask hypothyroidism
• Glucose metabolism: Fasting glucose/HbA1c annually (GH is diabetogenic)
• Bone age annually
• Scoliosis screening (rapid growth may worsen spinal curvature)

Contraindications:

• Active malignancy
• Severe, unstable HCM (relative contraindication)
• Closed epiphyses (no growth potential remaining)

Psychosocial Benefits:

• Improved self-esteem and body image
• Reduced social stigma associated with short stature
• Quality of life improvements reported

Pubertal Management:

• Delayed puberty common (50-60%): Evaluation if no pubertal signs by age 14 (males) or 13 (females)
• Males with severe delay or micropenis:
  • Low-dose testosterone supplementation (50-100 mg IM monthly, gradually increased)
  • Induces virilization, supports psychosocial development
  • Does not compromise final height if appropriately dosed
• Females: Estrogen supplementation rarely needed; delayed menarche typically occurs spontaneously by age 16-17

Hypothyroidism:

• Occurs in 5-10%
• Standard levothyroxine replacement if diagnosed
• Monitor TSH annually

Hematologic Management

Bleeding Diathesis: [16]

Preoperative Assessment:

• Mandatory comprehensive coagulation evaluation before any surgery, including minor procedures (dental extractions, tonsillectomy)
• Even if prior screening (PT/aPTT) normal, obtain:
  • Factor assays (VIII, XI, XII)
  • Von Willebrand panel
  • Platelet function testing
• Detailed bleeding history (prior surgeries, dental procedures, trauma)

Perioperative Management Strategies:

Factor Deficiencies:

• Factor XI deficiency (most common):

  • "Mild deficiency (activity 20-50%): May not require treatment for minor surgery"
  • "Moderate-severe deficiency (activity less than 20%):"
    • Tranexamic acid (antifibrinolytic): 10-25 mg/kg IV/PO TID
    • Fresh frozen plasma (FFP): 10-15 mL/kg if major surgery or active bleeding
    • Factor XI concentrate: Available in some countries (not FDA-approved in US)

• Von Willebrand disease:

  • "Desmopressin (DDAVP): 0.3 μg/kg IV over 30 minutes"
    • Releases endogenous vWF from endothelial stores
    • Perform trial dose with pre/post vWF levels to assess response
    • Effective in Type 1 vWD
  • "vWF-containing factor VIII concentrate: For non-responders or Type 2/3 vWD"

• Other factor deficiencies: Specific factor replacement as needed

Platelet Dysfunction:

• Tranexamic acid: First-line for mild-moderate dysfunction
• DDAVP: May improve platelet function in some cases
• Platelet transfusion: Reserved for severe bleeding or major surgery in severe dysfunction
• Avoid antiplatelet agents: No aspirin, NSAIDs (use acetaminophen for pain)

Minor Procedures:

• Dental extractions, tonsillectomy:
  • Tranexamic acid (10 mg/kg PO TID starting 1 day before, continuing 5-7 days after)
  • DDAVP (if vWD or responsive platelet dysfunction)
  • Local hemostatic measures (fibrin glue, topical thrombin)
  • Close postoperative monitoring

Major Surgery:

• Multidisciplinary planning (hematology, anesthesia, surgery)
• Factor replacement as indicated
• Antifibrinolytic therapy
• Minimize tissue trauma
• Postoperative drain monitoring
• Extended hospitalization for observation

Myeloproliferative Disorders:

• JMML surveillance: In infants with PTPN11 or KRAS mutations, monitor for hepatosplenomegaly, cytopenia
• If JMML develops: Hematology/oncology referral; treatment typically requires hematopoietic stem cell transplantation

Lymphatic Management

Chylothorax: [28]

Conservative Management (first-line):

• Medium-chain triglyceride (MCT) diet:

  • MCTs absorbed directly into portal circulation, bypassing lymphatics
  • Reduces chyle production, allowing thoracic duct to heal
  • Specialized MCT formula for infants
  • MCT oil supplementation for older children

• Total parenteral nutrition (TPN):

  • Complete bowel rest maximally reduces chyle flow
  • Reserved for severe/refractory cases

• Octreotide (somatostatin analog):

  • Reduces splanchnic blood flow and lymph production
  • "Dose: 1-10 μg/kg/day IV or subcutaneous"
  • Variable efficacy; case reports suggest benefit

Interventional Management:

• Thoracentesis: Drainage of pleural fluid for symptomatic relief
• Chest tube placement: Continuous drainage in large/recurrent effusions
• Pleurodesis: Chemical or surgical obliteration of pleural space (prevents re-accumulation)
• Thoracic duct ligation: Surgical intervention for refractory cases
  • Technically challenging in infants
  • Success rates variable

Peripheral Lymphedema:

• Compression garments: Custom-fitted for affected limbs
• Manual lymphatic drainage: Specialized massage technique
• Complete decongestive therapy: Multimodal approach (compression, exercise, skin care)
• Surgical debulking: Rarely indicated for severe, refractory cases

Protein-Losing Enteropathy (Intestinal Lymphangiectasia):

• MCT diet (as above)
• High-protein diet to compensate for losses
• Fat-soluble vitamin supplementation (A, D, E, K)
• Albumin infusions if severe hypoalbuminemia with edema
• Octreotide in refractory cases

Genitourinary Management

Cryptorchidism: [32]

Timing of Intervention:

• Orchiopexy (surgical testicular descent) recommended by age 12-18 months
• Rationale: Preserves fertility potential, reduces (but does not eliminate) malignancy risk, prevents testicular torsion
• Delayed beyond 18 months associated with progressive impairment of spermatogenesis

Surgical Approach:

• Standard inguinal or scrotal orchiopexy
• If intra-abdominal testis: Staged Fowler-Stephens procedure or laparoscopic orchiopexy

Long-term Fertility:

• Even after orchiopexy, reduced testicular volume and oligospermia common [37]
• Sertoli cell dysfunction contributes to impaired spermatogenesis
• Fertility preserved in many but not all males
• Semen analysis and fertility counseling recommended in adulthood

Renal Anomalies:

• Surgical correction if obstructive or associated with recurrent infections
• Nephrologist referral for significant functional impairment

Developmental and Educational Interventions

Early Intervention (0-3 years):

• Physical therapy: Address hypotonia, gross motor delay, promote motor milestones
• Occupational therapy: Fine motor skills, feeding difficulties, sensory processing
• Speech therapy: Oral motor dysfunction, articulation, language development
• Enrollment in Early Intervention programs (government-funded in many countries)

School-Age (> 5 years):

• Comprehensive neuropsychological evaluation: Identify specific learning disabilities (particularly visual-spatial, mathematics)
• Individualized Education Plan (IEP) or 504 Plan:
  • "Accommodations: Extended time on tests, preferential seating, visual aids"
  • "Modifications: Adjusted curriculum if intellectual disability present"
  • "Related services: Continued speech/OT/PT as needed"
• Special education support: Resource room, specialized instruction for 30-50% requiring intensive support
• ADHD management: Behavioral interventions; stimulant medication (methylphenidate, amphetamines) if indicated
• Social skills training: For social communication difficulties, anxiety

Transition Planning (Adolescence):

• Vocational counseling
• Transition from pediatric to adult medical care
• Reproductive counseling and genetic counseling for family planning
• Independent living skills assessment and support

Ophthalmologic and Audiologic Management

Vision:

• Refractive error correction: Glasses or contact lenses
• Strabismus management:
  • Patching for amblyopia
  • Surgical correction if persistent/severe
• Ptosis: Surgical correction if severe and affecting vision (obstructing visual axis) or for cosmetic concerns in adolescence

Hearing:

• Hearing aids: For sensorineural hearing loss
• Tympanostomy tubes: For recurrent otitis media with effusion causing conductive hearing loss
• Educational accommodations: Preferential seating, FM system (assistive listening device)

Anesthetic and Surgical Considerations

Noonan syndrome patients are high-risk anesthetic candidates requiring specialized perioperative management: [20]

Preoperative Assessment:

• Airway evaluation:

  • Assess for micrognathia, short neck, limited neck extension
  • Mallampati score
  • Consider fiberoptic intubation or videolaryngoscopy availability

• Cardiac evaluation:

  • Recent echocardiogram (less than 6 months)
  • ECG
  • Cardiology clearance, particularly if HCM or significant PS

• Hematology evaluation:

  • Comprehensive coagulation assessment (as detailed above)
  • Hemostasis plan established with hematology

• Cervical spine imaging if atlanto-axial instability suspected (rare but reported)

Intraoperative Considerations:

Airway Management:

• Difficult intubation rate: 10-20% in Noonan syndrome
• Preparation: Have difficult airway cart available, experienced anesthesiologist, ENT backup
• Consider awake or sedated fiberoptic intubation for anticipated difficult airway

Hemodynamic Management:

• Pulmonary stenosis:

  • Maintain preload (RV-dependent)
  • Avoid hypovolemia
  • Optimize oxygenation and ventilation

• Hypertrophic cardiomyopathy (higher risk):

  • "Avoid tachycardia: Reduces diastolic filling time, worsens LVOT obstruction"
  • "Maintain preload: Hypovolemia dramatically worsens dynamic obstruction"
  • "Avoid positive inotropes: Worsen LVOT gradient"
  • "Preferred agents: Beta-blockers available, phenylephrine (pure alpha-agonist) for hypotension"
  • "High-risk period: Induction and emergence (hemodynamic instability)"

Bleeding Management:

• Meticulous surgical hemostasis
• Antifibrinolytic prophylaxis (tranexamic acid)
• Factor replacement as planned preoperatively
• Consider cell saver for major surgery

Postoperative Considerations:

• Extended monitoring (PACU/ICU) for cardiac patients
• Monitor for delayed bleeding (particularly tonsillectomy, adenoidectomy)
• Early mobilization to reduce lymphatic complications (chylothorax risk after thoracic surgery)

Genetic Counseling and Family Screening

Index Patient Counseling:

• Autosomal dominant inheritance with 50% transmission risk to offspring
• Prenatal diagnosis available for future pregnancies
• Importance of cardiac screening before pregnancy (maternal HCM carries obstetric risks)

Family Screening:

• Clinical examination of first-degree relatives (parents, siblings)
• May identify mildly affected parent with de novo case (recurrence risk for siblings low)
• If affected parent identified: 50% recurrence risk; consider testing siblings
• Cascade genetic testing of at-risk relatives once familial mutation identified

Reproductive Options:

• Natural conception with 50% transmission risk
• Prenatal diagnosis (CVS/amniocentesis) with option for pregnancy termination
• Preimplantation genetic testing (PGT): IVF with embryo testing before transfer, selecting unaffected embryos
• Gamete donation
• Adoption

Lifestyle and Supportive Measures

Physical Activity:

• Encourage general physical activity for health benefits (obesity prevention, cardiovascular fitness)
• Restrictions in HCM: No competitive sports if moderate-severe HCM; individualized based on cardiology assessment
• Swimming encouraged (low-impact, cardiovascular benefit)

Diet:

• Balanced, nutritious diet
• High-calorie supplementation in infancy for failure to thrive
• MCT diet if lymphatic complications present

Psychosocial Support:

• Patient support organizations:
  • "Noonan Syndrome Association (UK): noonansyndrome.org"
  • "RASopathies Network: rasopathiesnet.org"
• Peer support groups: Connect families, share experiences
• Mental health support: Counseling for anxiety, depression, body image concerns (particularly adolescence)
• School advocacy: Ensure appropriate educational accommodations

Transition to Adult Care:

• Gradual transition from pediatric to adult specialists (cardiology, endocrinology)
• Adult congenital heart disease (ACHD) programs for cardiac follow-up
• Ensure patient understanding of condition, medications, surveillance needs (transition readiness assessment)
• Vocational planning and employment support

Novel and Emerging Therapies

MEK Inhibitors: [22]

The identification of Noonan syndrome as a RASopathy with hyperactive MAPK signaling has opened therapeutic possibilities targeting the pathway directly.

Trametinib:

• Oral MEK1/2 inhibitor, FDA-approved for BRAF-mutant melanoma and lung cancer
• Clinical trials in RASopathy-associated HCM: Ongoing and reporting preliminary results
• Mechanism: Inhibits MEK (downstream of RAS/RAF), reducing ERK activation and downstream proliferative signaling
• Evidence: Case series and early-phase trials demonstrate:
  • Regression of left ventricular hypertrophy (reduced septal thickness)
  • Reduction in LVOT gradients
  • Improved diastolic function
  • Benefits observed within 3-6 months of treatment
• FDA Breakthrough Therapy Designation (2024): Granted for RASopathy-associated HCM, expediting development
• Adverse effects:
  • Rash (acneiform eruption, xerosis)
  • Diarrhea
  • Peripheral edema
  • Concerns about effects on growth and development in children (under investigation)
  • Ophthalmologic effects (retinal vein occlusion, reported in adult cancer trials)
• Current status: Investigational; not yet FDA-approved for Noonan syndrome
• Future directions: Trials expanding to other RASopathy manifestations (lymphatic dysfunction, neurocognitive deficits)

Other MAPK Pathway Inhibitors:

• RAF inhibitors, ERK inhibitors under investigation in preclinical models
• Combination therapies to minimize resistance

Gene Therapy:

• Preclinical research stage
• Challenges: Germline disorder affecting multiple organ systems; correction would require early (prenatal or neonatal) intervention

---

8. Prognosis and Long-term Outcomes

Overall Survival and Life Expectancy

General Prognosis: Most individuals with Noonan syndrome have normal or near-normal life expectancy with appropriate medical management. [40] The prognosis has significantly improved over recent decades due to:

• Earlier diagnosis and cardiac intervention
• Improved cardiac surgical techniques
• Systematic surveillance protocols detecting complications early
• Growth hormone therapy improving quality of life
• Multidisciplinary care models

Mortality Risk Factors: The primary determinants of reduced life expectancy are cardiac complications: [13,14]

1. Hypertrophic cardiomyopathy:

   • Most significant mortality risk
   • Sudden cardiac death risk: 2-4% in RASopathy-associated HCM (lower than familial HCM without syndrome, ~6%)
   • Heart failure progression in severe, refractory cases
   • Risk highest in RAF1-associated HCM

2. Severe pulmonary stenosis:

   • Right heart failure if untreated
   • Generally excellent prognosis with timely intervention

3. Lymphatic complications:

   • Neonatal mortality from severe hydrops fetalis (particularly RIT1 mutations)
   • Chylothorax causing respiratory failure
   • Protein-losing enteropathy with severe hypoalbuminemia

4. Malignancy:

   • JMML in infancy (rare but significant)
   • Slightly elevated overall cancer risk

Favorable Prognostic Factors:

• Early diagnosis enabling proactive management
• Absence of HCM or only mild HCM
• Mild cardiac lesions (small ASD, mild PS)
• PTPN11 or SOS1 genotypes (generally milder cardiac phenotype than RAF1)
• Normal or near-normal intellectual development

Cardiovascular Long-term Outcomes

Pulmonary Stenosis:

• Post-intervention outcomes generally excellent
• Balloon valvuloplasty: 60-70% achieve significant gradient reduction (> 50% reduction) [12]
• Surgical valvotomy: > 85% have good long-term outcomes
• Restenosis: Occurs in 20-30%, may require repeat intervention
• Lifelong follow-up required: Residual stenosis, pulmonary regurgitation (if valve damaged during intervention), right ventricular dysfunction
• Endocarditis risk: Low; prophylaxis not routinely recommended per current guidelines

Hypertrophic Cardiomyopathy:

• Variable natural history: [13,14]
  • Some remain stable with mild hypertrophy
  • Progressive worsening in 30-40%, particularly RAF1 mutations
  • Regression reported rarely, particularly in young children
• Sudden cardiac death risk: 2-4% overall; higher in those with risk factors
• Heart failure: End-stage progression in severe, refractory cases; may require transplantation (rare)
• Atrial fibrillation: Develops in 10-20% of adults with long-standing HCM
• Lifelong surveillance mandatory: Annual cardiology assessment minimum; echo every 6-12 months
• Activity restrictions: Vary by severity; significantly impact quality of life for some

Novel Therapies (MEK Inhibitors): [22]

• Emerging evidence suggests potential to reverse HCM rather than merely manage symptoms
• If confirmed in larger trials, could fundamentally alter prognosis for RAF1-associated and severe HCM cases
• Long-term safety and efficacy data still accumulating

Growth and Endocrine Outcomes

Untreated Short Stature:

• Mean adult height approximately -2.3 to -2.5 SD: [27]
  • Males: ~162 cm (5'4")
  • Females: ~153 cm (5'0")
• Significant psychosocial impact: Body image concerns, social stigma, reduced quality of life

Growth Hormone Treatment Outcomes: [34]

• Near-adult height gain: 1.3-1.8 SD (~8-13 cm or 3-5 inches)
• Best outcomes: Early initiation (age 4-6 years), continued treatment until growth plates fuse
• Post-GH adult height: Approaches low-normal range for many
• Psychosocial benefits: Improved self-esteem, quality of life, social integration
• Limitations: Does not fully normalize height in most cases; ongoing treatment burden (daily injections)

Pubertal Outcomes:

• Delayed but generally complete pubertal development
• Fertility preserved in majority (both males and females)
• Males: Oligospermia more common than general population; successful paternity reported in 40-60% [37]
• Females: Successful pregnancy common; obstetric considerations include cardiac status (HCM complicates pregnancy), bleeding risk (postpartum hemorrhage)

Neurodevelopmental and Educational Outcomes

Intellectual Outcomes: [29]

• Majority function in normal or borderline range: 70-85% have IQ > 70
• Mean IQ ~85-90 (low-normal)
• Genotype-dependent:
  • "SOS1: Usually normal IQ, excellent academic outcomes"
  • "PTPN11: Borderline to low-normal, most attend mainstream school"
  • "KRAS: Higher rates of intellectual disability, often requiring special education"

Academic Achievement:

• 30-50% require special education support or significant accommodations
• Specific learning disabilities common: Mathematics, visual-spatial reasoning
• Verbal skills relatively preserved
• Long-term educational attainment: Variable
  • Many complete high school
  • College/university attendance lower than general population but achievable for many
  • Vocational training successful for those with greater cognitive impairment

Employment and Independence:

• Most adults achieve independence in activities of daily living
• Employment rates: 50-70% in competitive or supported employment settings
• Job types: Wide range, dependent on cognitive abilities and interests
• Challenges: Social anxiety, executive function difficulties may impact job performance
• Supported employment programs beneficial for some

Social and Behavioral Outcomes:

• Generally sociable, pleasant personality
• Social anxiety increases in adolescence/adulthood (20-30%)
• Romantic relationships and marriage: Achievable for many; limited data on rates
• Quality of life: Studies report good overall quality of life, though lower than age-matched controls
• Psychosocial support and mental health services improve outcomes

Reproductive Outcomes

Males: [32,37]

• Fertility: Reduced compared to general population but preserved in many
• Successful paternity reported in 40-60%
• Contributing factors to reduced fertility:
  • History of cryptorchidism (even after orchiopexy)
  • Primary Sertoli cell dysfunction
  • Oligospermia (low sperm count)
• Reproductive counseling: Semen analysis in adulthood; assisted reproductive technologies (IUI, IVF with ICSI) may be needed
• Genetic transmission: 50% risk to offspring if conception achieved

Females:

• Fertility: Generally preserved; numerous reports of successful pregnancies
• Pregnancy considerations:
  • Preconception cardiac assessment mandatory (HCM complicates pregnancy; may contraindicate pregnancy if severe)
  • "Increased obstetric risks: Preterm delivery, bleeding complications (postpartum hemorrhage due to bleeding diathesis)"
  • "Genetic counseling: 50% transmission risk to offspring; prenatal testing available"
  • "Multidisciplinary prenatal care: High-risk obstetrics, cardiology, hematology"
• Outcomes: Most pregnancies successful with appropriate monitoring

Malignancy Risk and Surveillance

Overall Cancer Risk: [35]

• Approximately 8-fold increased risk of childhood cancer compared to general population
• Absolute risk remains low (less than 5% develop malignancy)

Specific Malignancies:

• Juvenile myelomonocytic leukemia (JMML):

  • Most characteristic malignancy
  • Occurs in infancy (typically less than 2 years)
  • Presents with hepatosplenomegaly, leukocytosis, monocytosis, thrombocytopenia
  • Strong association with PTPN11 and KRAS mutations (somatic PTPN11/NRAS/KRAS mutations also found in sporadic JMML)
  • "Treatment: Hematopoietic stem cell transplantation"
  • "Prognosis: Variable; 5-year survival ~50% with transplant"

• Other hematologic malignancies: ALL (acute lymphoblastic leukemia), AML (acute myeloid leukemia)—case reports, unclear if true increased risk

• Solid tumors: Neuroblastoma, rhabdomyosarcoma—case reports, no clear consistent pattern

Surveillance:

• No consensus guidelines for cancer screening
• Awareness and clinical vigilance (unexplained symptoms, organomegaly, cytopenias warrant investigation)
• PTPN11/KRAS mutation carriers in infancy: Monitor for hepatosplenomegaly, obtain CBC if concerning

Contrast with Costello Syndrome:

• Costello syndrome (HRAS mutations) carries much higher malignancy risk (~15% lifetime)
• Rhabdomyosarcoma and transitional cell carcinoma of bladder characteristic
• Tumor surveillance protocols established for Costello syndrome

Adult Health Issues

Cardiovascular:

• Lifelong cardiology follow-up required
• Transition to adult congenital heart disease (ACHD) programs
• Potential late complications: Arrhythmias, heart failure, need for valve replacement
• Endocarditis risk if complex lesions or prosthetic valves

Musculoskeletal:

• Scoliosis progression in adulthood if present
• Joint pain and early degenerative changes (secondary to hypermobility)
• Osteoporosis risk not clearly defined

Mental Health:

• Anxiety disorders persist or emerge in adulthood
• Depression risk elevated
• Access to mental health services important

Metabolic:

• Obesity risk increased (sedentary lifestyle if activity-restricted due to HCM, hormonal factors)
• Diabetes risk possibly elevated (limited data)

Quality of Life

Patient-Reported Outcomes:

• Studies report generally good quality of life despite medical complexities [41]
• Primary impacts on quality of life:
  • Short stature (improved with GH therapy)
  • Cardiac activity restrictions (for HCM)
  • Learning difficulties and educational challenges
  • Social anxiety and peer relationships
  • Facial appearance (cosmetic concerns in adolescence)

Factors Improving Quality of Life:

• Early diagnosis and multidisciplinary management
• Growth hormone therapy
• Educational support and accommodations
• Peer support groups and patient organizations
• Mental health services
• Successful transition to independent adulthood

Ongoing Research:

• Natural history studies tracking long-term outcomes
• Quality of life assessments in adult cohorts
• Impact of emerging therapies (MEK inhibitors) on functional outcomes

---

9. Patient and Family Education

Understanding the Diagnosis

What is Noonan Syndrome? Noonan syndrome is a genetic condition present from birth that affects how the body develops. It is caused by a change (mutation) in one of several genes that help control cell growth and development. The condition affects multiple body systems, particularly the heart, growth, facial features, and learning abilities.

How Common Is It? Noonan syndrome affects approximately 1 in 1,000 to 1 in 2,500 babies, making it one of the more common genetic conditions. It affects boys and girls equally.

What Causes It? Noonan syndrome is caused by mutations in genes involved in a cellular pathway called the RAS-MAPK pathway, which controls cell growth and division. The most commonly affected gene is PTPN11 (in about half of cases), but several other genes can also cause the syndrome. About half of children with Noonan syndrome inherit the mutation from a parent, while the other half have a new mutation that occurred spontaneously.

Is It the Same as Turner Syndrome? No. Noonan syndrome was historically called "Male Turner syndrome" because of similar features (webbed neck, short stature), but they are completely different conditions:

• Turner syndrome only affects females and is caused by a missing X chromosome (not a gene mutation)
• Turner syndrome causes left-sided heart problems (like coarctation of the aorta), while Noonan syndrome typically causes right-sided problems (like pulmonary valve stenosis)
• Children with Noonan syndrome have normal chromosomes

Common Questions from Families

Q: Will my child have a normal lifespan? A: Most children with Noonan syndrome grow up to be healthy adults with normal or near-normal life expectancy. The main factor affecting long-term health is heart disease. With modern cardiac care, including surgery when needed, the vast majority of people with Noonan syndrome live full, active lives.

Q: Will my child have intellectual disability? A: Most children with Noonan syndrome have normal or near-normal intelligence. The average IQ is slightly lower than the general population (around 85-90 instead of 100), but most children attend regular schools. About 30-50% need some extra educational support, particularly for subjects involving visual-spatial skills like mathematics. Some children have more significant learning challenges, but severe intellectual disability is uncommon. The specific gene involved influences cognitive outcomes.

Q: Will my child need heart surgery? A: About 80-90% of children with Noonan syndrome have some type of heart problem, but not all need surgery. The most common issue is narrowing of the pulmonary valve (pulmonary stenosis), which can often be treated with a balloon procedure through a catheter rather than open-heart surgery. About 20% have thickening of the heart muscle (hypertrophic cardiomyopathy), which is usually managed with medication. Your cardiologist will monitor your child's heart and recommend treatment only if needed.

Q: Why does my child bruise so easily? A: Many children with Noonan syndrome (40-65%) have mild bleeding problems due to low levels of certain blood clotting factors or platelets that don't work perfectly. This usually causes easy bruising, nosebleeds, or bleeding longer from cuts. It's rarely dangerous for everyday activities, but it's very important to tell doctors about this before any surgery or dental procedures, so they can take precautions to prevent excessive bleeding.

Q: Will my child be short? A: Most children with Noonan syndrome are shorter than average. Without treatment, adult height is typically around 5 feet 4 inches for males and 5 feet for females. However, growth hormone treatment can help children grow taller. When started early (around age 4-6) and continued for several years, growth hormone can add 3-5 inches to adult height. Your endocrinologist (hormone specialist) can discuss whether this treatment is right for your child.

Q: Can my child participate in sports? A: It depends on the heart condition. Most children with mild heart problems or those whose heart problems have been successfully treated can participate in most sports and activities. However, children with hypertrophic cardiomyopathy (thickened heart muscle) may need to avoid competitive sports and very intense physical activity to reduce the risk of dangerous heart rhythms. Your cardiologist will provide specific guidance based on your child's individual heart condition. Regular physical activity is generally encouraged for overall health.

Q: Will my child be able to have children when they grow up? A: Fertility is possible for most people with Noonan syndrome, though it may be reduced compared to the general population:

• Boys: About 60-80% of boys are born with undescended testicles, which should be corrected surgically by age 12-18 months to preserve fertility. Even after correction, fertility may be somewhat reduced, but many men with Noonan syndrome have successfully fathered children.
• Girls: Fertility is usually normal. Women with Noonan syndrome can have successful pregnancies, though they need close monitoring due to potential heart and bleeding complications.
• Important: Any child of a person with Noonan syndrome has a 50% chance of inheriting the condition. Genetic counseling can help families understand their options.

Q: Is there a cure? A: Currently, there is no cure for Noonan syndrome because it is caused by a genetic change present in every cell of the body. However, most of the medical problems can be effectively managed with treatment:

• Heart problems can be treated with procedures or surgery
• Growth hormone can improve height
• Educational support helps with learning
• Therapy (physical, occupational, speech) helps with developmental delays

Exciting new research is investigating medications called MEK inhibitors that may actually reverse some problems (like heart muscle thickening) by targeting the underlying pathway that's affected in Noonan syndrome. These are currently in clinical trials.

Q: What medical care will my child need? Your child will need regular monitoring by a team of specialists:

• Cardiologist (heart doctor): At least every 1-2 years, more often if heart problems are present
• Endocrinologist (hormone doctor): Monitor growth and consider growth hormone treatment
• Developmental pediatrician: Assess development and learning
• Ophthalmologist (eye doctor): Check vision every 1-2 years
• Audiologist: Check hearing every 2-3 years
• Other specialists as needed based on your child's specific issues

Regular check-ups with your primary care pediatrician are also important to coordinate care and address any new concerns.

Q: How can I help my child thrive?

• Early intervention: Starting therapies (physical, occupational, speech) early in life significantly improves outcomes
• Educational support: Work with your child's school to ensure appropriate accommodations and support
• Medical compliance: Keep up with specialist appointments and recommended treatments
• Emotional support: Children may face challenges related to appearance, height, or learning differences. Support groups can connect you with other families who understand
• Advocacy: Be your child's advocate—ensure teachers, coaches, and healthcare providers understand the condition
• Positive outlook: Focus on your child's strengths and abilities. Most children with Noonan syndrome grow up to lead fulfilling, independent lives

Resources and Support

Patient Organizations:

• The Noonan Syndrome Association (UK): noonansyndrome.org.uk
  • Information, family support, annual conferences
• The Noonan Syndrome Foundation (USA): noonansyndromefoundation.org
  • Resources, research updates, family connections
• RASopathies Network: rasopathiesnet.org
  • Covers Noonan syndrome and related conditions
  • Research initiatives, family resources

Online Communities:

• Facebook support groups connect families worldwide
• RASopathies Network hosts virtual family conferences

Educational Resources:

• GeneReviews Noonan Syndrome chapter: Comprehensive medical information for families and professionals
• Patient information leaflets from genetics departments

Financial and Practical Support:

• Disability benefits may be available depending on severity (varies by country)
• Special education services provided through schools (US: IDEA; UK: EHCP)
• Make-A-Wish and similar organizations for children with serious medical conditions

---

10. Key Clinical Guidelines and Evidence

Major Clinical Practice Guidelines

1. Romano AA, et al. "Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines." Pediatrics. 2010. [15]

• Comprehensive consensus guidelines from the Noonan Syndrome Guideline Development Group
• Evidence-based recommendations for diagnosis, genetic testing, and multidisciplinary management
• Surveillance protocols for cardiac, endocrine, developmental, hematologic complications
• Key recommendations:
  • Echocardiogram and ECG at diagnosis and periodic surveillance (every 3-5 years if normal; more frequently if abnormalities present)
  • Coagulation screening before surgical procedures
  • Growth monitoring on Noonan-specific growth charts
  • Developmental screening and early intervention referrals
• Strength: Based on systematic literature review and expert consensus; widely adopted internationally

2. Roberts AE, et al. "Noonan Syndrome." The Lancet. 2013. [3]

• Authoritative review summarizing clinical features, molecular genetics, natural history, and management
• Updated genotype-phenotype correlations based on molecular era discoveries
• Management algorithms for cardiac and non-cardiac manifestations
• Significance: High-impact journal publication; frequently cited reference standard

3. Linglart A, Gelb BD. "Congenital Heart Defects in Noonan Syndrome: Diagnosis, Management, and Treatment." American Journal of Medical Genetics Part C. 2020. [12]

• Focused guideline on cardiac manifestations
• Detailed approach to pulmonary stenosis, HCM, and other cardiac lesions
• Intervention thresholds and modalities
• Key recommendations:
  • Balloon valvuloplasty first-line for PS, but lower success in dysplastic valves
  • HCM surveillance every 6-12 months; activity restrictions based on risk stratification
  • Emerging role of MEK inhibitors for severe HCM

4. Growth Hormone Treatment Guidelines: Multiple publications including FDA approval documents (2007)

• rhGH approved for Noonan syndrome at doses 0.033-0.066 mg/kg/day
• Indications: Height -2.25 SD or less
• Cardiac surveillance during treatment

Landmark Studies and Key Evidence

Molecular Discovery:

Tartaglia M, et al. "Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome." Nature Genetics. 2001. [8]

• First identification of genetic cause of Noonan syndrome
• Established PTPN11 as causative gene in ~50% of cases
• Proved Noonan syndrome is a RASopathy
• Impact: Transformed understanding from purely clinical syndrome to molecular disorder; enabled genetic testing and targeted therapy research

Subsequent gene discoveries:

• SOS1 (Roberts et al., 2007) [26]
• RAF1 (Pandit et al., 2007; Razzaque et al., 2007) [18]
• RIT1 (Aoki et al., 2013) [19]
• Additional genes identified in subsequent years

Genotype-Phenotype Correlations:

Tartaglia M, et al. "PTPN11 Mutations in Noonan Syndrome: Molecular Spectrum, Genotype-Phenotype Correlation, and Phenotypic Heterogeneity." American Journal of Human Genetics. 2002. [17]

• Large cohort analyzing PTPN11 mutations and associated phenotypes
• Established correlation between specific mutations and cardiac lesions
• Demonstrated variable expressivity even within families

RAF1 and HCM Association: Pandit B, et al.; Razzaque MA, et al. (2007) [18]

• Identified strong association between RAF1 mutations and hypertrophic cardiomyopathy (75-95%)
• Clinically important for risk stratification and surveillance intensity

RIT1 and Lymphatic Dysfunction: Aoki Y, et al. (2013); subsequent cohort studies [19]

• RIT1 mutations strongly associated with fetal hydrops and neonatal lymphatic complications
• Guides prenatal counseling and neonatal management

Growth Hormone Therapy Efficacy:

National Cooperative Growth Study (NCGS) and KIGS (Pfizer International Growth Database):

• Large registry studies demonstrating efficacy and safety of rhGH in Noonan syndrome [27,34]
• Near-adult height gain of 1.3-1.8 SD (8-13 cm)
• No significant increase in cardiac complications during treatment
• Supported FDA approval (2007)

Cardiac Outcomes:

Pulmonary Stenosis Intervention Studies:

• Multiple cohort studies demonstrating lower success rates of balloon valvuloplasty in dysplastic Noonan syndrome PS (60%) vs. non-syndromic PS (85-90%) [12]
• Higher restenosis rates
• Informed intervention strategies

HCM Natural History: Wilkinson JD, et al.; Pediatric Cardiomyopathy Registry [13]

• Noonan syndrome-associated HCM has better prognosis than familial HCM
• Sudden cardiac death risk ~2-4% (vs. ~6% in non-syndromic HCM)
• Progressive worsening in 30-40%, particularly RAF1 mutations

MEK Inhibitor Trials (Emerging):

Trametinib in RASopathy-Associated HCM: [22]

• Ongoing clinical trials (Phase II/III)
• Published case series and early trial results demonstrate:
  • Regression of LV hypertrophy (reduced septal thickness by 20-40%)
  • Reduction in LVOT gradients
  • Improvement in functional status
  • Adverse effects manageable (rash, diarrhea)
• FDA Breakthrough Therapy Designation (2024): Expedited development pathway
• Potential paradigm shift: From symptomatic management to disease-modifying therapy

Studies in other RASopathy manifestations (lymphatic dysfunction, neurocognitive deficits) underway

Bleeding Diathesis:

Sharland M, et al. "A Clinical Study of Noonan Syndrome." Archives of Disease in Childhood. 1992. [16]

• Classic description of bleeding tendency in Noonan syndrome
• Factor XI deficiency most common
• Platelet dysfunction frequent
• Routine coagulation screening often normal despite bleeding risk

Neurodevelopmental Outcomes:

Pierpont EI, et al. "Genotype Differences in Cognitive Functioning in Noonan Syndrome." Genes, Brain and Behavior. 2009; Subsequent studies [29]

• Mean IQ 85-90 (low-normal range)
• Specific deficit in visual-spatial processing
• Genotype influences: SOS1 (normal IQ), KRAS (more severe impairment)
• Informed educational planning and genetic counseling

Fertility and Reproductive Outcomes:

Moniez S, et al. "Noonan Syndrome Males Display Sertoli Cell-Specific Primary Testicular Insufficiency." European Journal of Endocrinology. 2018. [37]

• Demonstrated primary testicular dysfunction beyond cryptorchidism
• Sertoli cell insufficiency impairs spermatogenesis
• Explains reduced fertility even after orchiopexy

Lymphatic Management:

Cox GE, et al. "Systematic Literature Review of Lymphatic Imaging-Guided Procedural Management of Noonan Syndrome." Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2022. [28]

• Review of interventions for chylothorax, lymphedema
• Conservative management (MCT diet) first-line
• Variable success of surgical interventions

Evidence Quality Summary

Evidence Gaps and Ongoing Research:

• Long-term outcomes of MEK inhibitor therapy
• Optimal dosing and duration of trametinib for HCM
• MEK inhibitors for non-cardiac manifestations
• Standardized cancer surveillance protocols
• Adult natural history and late complications
• Optimal educational interventions for neurocognitive deficits
• Fertility outcomes and reproductive technologies

---

11. References

1. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev. 2009;19(3):230-236. doi:10.1016/j.gde.2009.04.001

2. Rauen KA. The RASopathies. Annu Rev Genomics Hum Genet. 2013;14:355-369. doi:10.1146/annurev-genom-091212-153523

3. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013;381(9863):333-342. doi:10.1016/S0140-6736(12)61023-X [PMID: 23312968]

4. van der Burgt I. Noonan syndrome. Orphanet J Rare Dis. 2007;2:4. doi:10.1186/1750-1172-2-4 [PMID: 17222357]

5. Allanson JE, Roberts AE. Noonan Syndrome. 2001 Nov 15 [Updated 2019]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993-2025. PMID: 20301303

6. Noonan JA. Noonan syndrome revisited. J Pediatr. 1999;135(6):667-668. doi:10.1016/s0022-3476(99)70083-4

7. van der Burgt I, Berger R, Benninga M, et al. Noonan syndrome: clinical features and genetic aspects. Eur J Pediatr. 1994;153(7):457-461.

8. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29(4):465-468. doi:10.1038/ng772 [PMID: 11704759]

9. Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab. 2011;25(1):161-179. doi:10.1016/j.beem.2010.09.002

10. Yamamoto GL, Aguena M, Gos M, et al. Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome. J Med Genet. 2015;52(6):413-421. doi:10.1136/jmedgenet-2015-103018 [PMID: 25795793]

11. Tajan M, de Rocca Serra A, Valet P, Edouard T, Yart A. SHP2 sails from physiology to pathology. Eur J Med Genet. 2015;58(10):509-525. doi:10.1016/j.ejmg.2015.08.005 [PMID: 26341048]

12. Linglart A, Gelb BD. Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment. Am J Med Genet C Semin Med Genet. 2020;184(1):73-80. doi:10.1002/ajmg.c.31765 [PMID: 32022400]

13. Wilkinson JD, Lowe AM, Salbert BA, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012;164(3):442-448. doi:10.1016/j.ahj.2012.04.018

14. Prendiville TW, Gauvreau K, Tworog-Dube E, et al. Cardiovascular disease in Noonan syndrome. Arch Dis Child. 2014;99(7):629-634. doi:10.1136/archdischild-2013-305047

15. Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126(4):746-759. doi:10.1542/peds.2009-3207

16. Sharland M, Burch M, McKenna WM, Paton MA. A clinical study of Noonan syndrome. Arch Dis Child. 1992;67(2):178-183. doi:10.1136/adc.67.2.178

17. Tartaglia M, Kalidas K, Shaw A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70(6):1555-1563. doi:10.1086/340847 [PMID: 11992261]

18. Pandit B, Sarkozy A, Pennacchio LA, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39(8):1007-1012. doi:10.1038/ng2073

19. Aoki Y, Niihori T, Banjo T, et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet. 2013;93(1):173-180. doi:10.1016/j.ajhg.2013.05.021

20. Hernández-Martín S, Ruz-Caracuel I, Pian H, et al. Anesthetic implications of Noonan syndrome. Paediatr Anaesth. 2021;31(2):157-166. doi:10.1111/pan.14070

21. Allanson JE. Noonan syndrome. Am J Med Genet C Semin Med Genet. 2007;145C(3):274-279. doi:10.1002/ajmg.c.30138

22. De Brouchoven V, Lorand T, Bofferding M, et al. Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome. Front Pediatr. 2025;13:1475143. doi:10.3389/fped.2025.1475143 [PMID: 40041314]

23. Ilic I, Krasic S, Maric N, et al. Noonan Syndrome: Relation of Genotype to Cardiovascular Phenotype-A Multi-Center Retrospective Study. Genes (Basel). 2024;15(11):1463. doi:10.3390/genes15111463 [PMID: 39596663]

24. Tartaglia M, Martinelli S, Stella L, et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet. 2006;78(2):279-290.

25. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem. 2005;280(35):30984-30993.

26. Roberts AE, Araki T, Swanson KD, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet. 2007;39(1):70-74. doi:10.1038/ng1926

27. Limal JM, Parfait B, Cabrol S, et al. Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab. 2006;91(1):300-306. doi:10.1210/jc.2005-0983

28. Cox GE, Vance R, Daley DJ, et al. Systematic literature review of lymphatic imaging-guided procedural management of Noonan syndrome. J Vasc Surg Venous Lymphat Disord. 2022;10(5):1130-1138. doi:10.1016/j.jvsv.2022.03.017 [PMID: 35561969]

29. Pierpont EI, Pierpont ME, Mendelsohn NJ, et al. Genotype differences in cognitive functioning in Noonan syndrome. Genes Brain Behav. 2009;8(3):275-282. doi:10.1111/j.1601-183X.2008.00469.x

30. Digilio MC, Conti E, Sarkozy A, et al. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet. 2002;71(2):389-394.

31. van den Berg S, van Hoorn I, van der Burgt I, et al. Feeding difficulties in Noonan syndrome: a longitudinal study. J Pediatr Gastroenterol Nutr. 2019;69(2):166-171.

32. Elsawi MM, Pryor JP, Klufio G, Barnes C, Patton MA. Genital tract function in men with Noonan syndrome. J Med Genet. 1994;31(6):468-470. doi:10.1136/jmg.31.6.468

33. Allanson JE, Hall JG, Hughes HE, Preus M, Witt RD. Noonan syndrome: the changing phenotype. Am J Med Genet. 1985;21(3):507-514.

34. Cappa M, Cappa M, d'Aniello G, et al. Noonan Syndrome Growth Charts and Genotypes: 15-Year Longitudinal Single-Centre Study. Horm Res Paediatr. 2025;98(1):74-86. doi:10.1159/000540092 [PMID: 38964306]

35. Kratz CP, Franke L, Peters H, et al. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes. Br J Cancer. 2015;112(8):1392-1397. doi:10.1038/bjc.2015.75

36. McGhee E, Plank A, Pannone A, et al. Genotype-phenotype correlations with autism spectrum disorder-related traits in noonan syndrome and noonan syndrome with multiple lentigines: a cross-sectional study. Mol Autism. 2025;16(1):13. doi:10.1186/s13229-025-00681-1 [PMID: 41074228]

37. Moniez S, Pienkowski C, Lepage B, et al. Noonan syndrome males display Sertoli cell-specific primary testicular insufficiency. Eur J Endocrinol. 2018;179(6):387-395. doi:10.1530/EJE-18-0582 [PMID: 30325180]

38. Lee JY, Jeong J, Lee SY, et al. Gene signatures and genotype-phenotype correlations of sensorineural hearing loss in Noonan syndrome and related RASopathies. Sci Rep. 2025;15(1):4298. doi:10.1038/s41598-025-90635-7 [PMID: 40204880]

39. Croonen EA, Nillesen WM, Stuurman KE, et al. Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings. Eur J Hum Genet. 2013;21(9):936-942. doi:10.1038/ejhg.2012.281

40. Rippert E, Reef S, Mani B, et al. Longitudinal outcomes in Noonan syndrome. Genet Med. 2025;27(4):101355. doi:10.1016/j.gim.2025.101355 [PMID: 39807623]

41. Wingbermuehle E, Egger J, van der Burgt I, Verhoeven W. Neuropsychological and behavioral aspects of Noonan syndrome. Horm Res. 2009;72(Suppl 2):15-23. doi:10.1159/000243773

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and the most current evidence. Always consult appropriate specialists for patient-specific management decisions.